JORA HOVSEPIAN: Open Payments
NPI 1275117632 · SHERMAN OAKS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,742 in 132 payments from 25 companies in 2025. Trend: 2023 $2,302 · 2024 $3,727 · 2025 $3,742
Food & beverage: $3,742
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 23 | $558 |
| SK Life Science, Inc. | 13 | $445 |
| Neurelis, Inc. | 10 | $346 |
| ABBVIE INC. | 11 | $268 |
| Amneal Pharmaceuticals LLC | 9 | $252 |
| EMD Serono, Inc. | 9 | $217 |
| Teva Pharmaceuticals USA, Inc. | 6 | $213 |
| Lundbeck LLC | 7 | $209 |
| Otsuka America Pharmaceutical, Inc. | 9 | $190 |
| Biogen, Inc. | 5 | $132 |
Products named: VALTOCO, REXULTI, Zilbrysq, CREXONT, QULIPTA, AUSTEDO XR, VUMERITY, Nayzilam.
Industry payments across CA — which companies pay providers there.
